We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Higher Efficacy of Blood Gas and Electrolyte Analyzers Driving Adoption in ICUs and Emergency Care

By LabMedica International staff writers
Posted on 31 Aug 2022

Blood gas and electrolyte analyzers are extensively used for the patients with conditions such as diabetes, hemorrhage, drug overdose, and others. More...

These analyzers detect the blood levels, oxygen concentration, and several parameters for early diagnosis. The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 5.6% between 2022 to 2030, to reach USD 6.5 billion by 2030, driven by the increasing use of blood gas and electrolyte analyzers in intensive care units (ICUs) and emergency departments. Additionally, the growing adoption of electronic health records (EHR) and development of advanced blood gas analyzers with laboratory information systems, along with higher investment in healthcare services by governments across the world is also expected to drive market growth.

These are the latest findings of Fact.MR (Dublin, Ireland), a market research and consulting agency.

Integration of advanced technology in healthcare devices has been a boon to patients as well as the healthcare industry. The availability of portable blood analyzers coupled with the introduction of automated analyzers have led to increased demand in the market. Portable and fully automated blood and gas electrolyte analyzers require only anticoagulated blood sample and can measure multiple parameters. Hence, healthcare professionals are using these to improve the handling process and accuracy of blood tests. As a result, the demand for blood and gas electrolyte analyzers is predicted to surge by 1.5x over the forecast period.

Going forwards, the efficacy of blood gas and electrolytes in treating patients in critical and emergency situations is likely to drive demand. Consistent quality control and accuracy in error detection will continue to make blood gas and electrolyte analyzers the preferred choice for healthcare providers. Moreover, lack of alternative devices and techniques for measuring oxygen concentration and other parameters for chronic illnesses will also drive sales. However, the high cost of blood analyzers and electrolytes is likely to slow down their adoption rate, especially in the developing countries. In addition, the availability of refurbished devices and slow/non-approval of blood analyzers from FDA could hamper market growth.

By product type, the blood gas analyzers segment is expected to lead the market, owing to its growing use in disease detection. Based on modality, portable blood gas and electrolyte analyzers are anticipated to remain the preferred choice in the healthcare industry owing to their ease of use and affordability. In terms of end user, diagnostic centers and clinical laboratories are expected to witness a steady growth over the projection period. Geographically, North America is expected to be the world’s largest market for blood gas and electrolyte analyzers, with the U.S. leading the demand, while South Asia is expected to be the most lucrative market for blood gas and electrolyte analyzers, with India spearheading the region’s growth through 2022 and beyond.

 

 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.